NDAORALCAPSULE, EXTENDED RELEASE
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
11
Data completeness
6/8 — Strong
JORNAY PM (methylphenidate hydrochloride) by Teva is (cns) stimulant. First approved in 2018.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JORNAY PM is an extended-release oral capsule formulation of methylphenidate hydrochloride, a CNS stimulant approved in 2018 for ADHD treatment. The exact mechanism of therapeutic action in ADHD is not fully understood, but methylphenidate is believed to work through dopamine and norepinephrine modulation. The formulation is designed for evening dosing to support next-day symptom control.
$0.001BPart D
Peak5.8 years to LOEThe product is in peak commercial phase with modest Medicare Part D penetration, indicating a stable but niche market position requiring targeted managed care and physician engagement strategies.
Mechanism of Action
(CNS) stimulant. The exact mode of therapeutic action in ADHD is not known.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (11)
A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
Started Apr 2019
60 enrolled
Attention Deficit Hyperactivity DisorderGeneralized Anxiety DisorderSocial Anxiety Disorder+2 more
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder
Started Apr 2011
299 enrolled
Attention Deficit/Hyperactivity Disorder
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
Started Nov 2010
725 enrolled
Attention Deficit/Hyperactivity Disorder
Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Started Jul 2009
357 enrolled
Attention Deficit Disorder With Hyperactivity
Efficacy Study of Methylphenidate Hydrochloride to Reduce Fatigue in Prostate Cancer Patients Receiving Hormone Therapy
Started Jan 2008
33 enrolled
Prostatic NeoplasmsFatigue
Worked on JORNAY PM at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.